Abbott Laboratories (ABT) : Rathbone Brothers Plc scooped up 7,037 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 204,646 shares of Abbott Laboratories which is valued at $9,198,838.Abbott Laboratories makes up approximately 0.50% of Rathbone Brothers Plc’s portfolio.
Other Hedge Funds, Including , Sawgrass Asset Management reduced its stake in ABT by selling 3,950 shares or 0.98% in the most recent quarter. The Hedge Fund company now holds 399,099 shares of ABT which is valued at $17,939,500. Abbott Laboratories makes up approx 0.82% of Sawgrass Asset Management’s portfolio.Cobiz Investment Management reduced its stake in ABT by selling 14,035 shares or 34.73% in the most recent quarter. The Hedge Fund company now holds 26,372 shares of ABT which is valued at $1,185,421. Abbott Laboratories makes up approx 0.29% of Cobiz Investment Management’s portfolio.Markston International reduced its stake in ABT by selling 1,175 shares or 1.01% in the most recent quarter. The Hedge Fund company now holds 114,691 shares of ABT which is valued at $5,008,556. Abbott Laboratories makes up approx 0.45% of Markston International’s portfolio.Leavell Investment Management reduced its stake in ABT by selling 305 shares or 0.7% in the most recent quarter. The Hedge Fund company now holds 43,040 shares of ABT which is valued at $1,835,656. Abbott Laboratories makes up approx 0.26% of Leavell Investment Management’s portfolio.Physicians Financial Services boosted its stake in ABT in the latest quarter, The investment management firm added 266 additional shares and now holds a total of 6,897 shares of Abbott Laboratories which is valued at $290,295. Abbott Laboratories makes up approx 0.25% of Physicians Financial Services’s portfolio.
Abbott Laboratories closed down -0.24 points or -0.53% at $45.02 with 76,57,947 shares getting traded on Monday. Post opening the session at $45.06, the shares hit an intraday low of $44.88 and an intraday high of $45.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.